SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.

Andere Sprachen Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Aktien

002603

CNE1000015S0

002603

Pharmazeutika

Schlusskurs Shenzhen S.E. Andere Börsenplätze 13.02.2026			% 5 Tage	Veränd. 1. Jan.
17,40 ^CNY	-0,63 %		-3,76 %	+1,93 %

23.01.	Yiling Pharmas Tochterunternehmen erhält Zulassung für die Registrierung der Aniline-Profen-Injektion	MT
23.01.	Yiling Pharmaceutical erwartet 2025 Gewinnwende dank Umsatz-Erholung und Kostenkontrolle	MT

Andere Sprachen

23.01.	Yiling Pharma's Unit Gets Nod for Registration of Aniline Profen Injection
23.01.	Yiling Pharmaceutical Expects 2025 Profit Swing on Revenue Recovery, Cost Control
22.01.	Shijiazhuang Yiling Pharmaceutical sees 2025 net profit 1.2-1.3 billion yuan
08.01.	Chinese Drug Regulator Accepts Yiling Pharmaceutical's Application for Qilong Dingchuan Tablets
08.01.	Yiling Pharmaceutical Unit Gets Nod to Market Dapagliflozin
08.01.	Yiling Pharmaceutical Unit Gets Registration Certificate for Herpes Drug
08.12.	Yiling Pharmaceutical's Qifang Bitong Tablets Placed in China's Insurance Drug List
28.11.	Yiling Pharmaceutical Withdraws Drug Registration Application for Chaihuang Lidan Capsules
13.11.	Yiling Pharmaceutical Unit Gets China Nod for Alzheimer's Drug Raw Material
27.10.25	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025
27.10.25	Yiling pharmaceutical Q3 net profit up 1264.6% Y/Y
16.09.25	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Interim Cash Dividend on A Shares for 2025, Payable on 22 October 2025
28.08.25	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Proposes Interim Cash Dividend for the First Half of 2025
28.08.25	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025
27.08.25	Shijiazhuang Yiling Pharmaceutical H1 net profit up 26.0% Y/Y
11.07.25	Yiling Pharmaceutical Receives Regulatory Greenlight for Review of Banxia Baizhu Tianma Granules
08.07.25	Yiling Pharmaceutical Gets Nod to Trial G201-Na Capsule
28.04.25	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025
22.01.25	Yiling Pharmaceutical's Unit Gets Registration Certificate for Qifangbitong Tablets
08.01.25	Yiling Pharma Withdraws Plans to Trial Assisted Reproductive Drug
02.12.24	Yiling Pharmaceutical Unit Gets Nod to Market Simvastatin Tablets in US
29.11.24	Shijiazhuang Yiling Pharmaceutical's Tongluo Mingmu Capsules Added to National Medical Insurance Catalog
28.10.24	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024
18.10.24	Shijiazhuang Yiling Pharmaceutical Reproduction-Related Drug Gets NMPA's Nod for Clinical Trials
27.08.24	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen MarketScreener Artikel MarketScreener Analysen Trading-Ideen

Andere Sprachen Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Aktien

002603

CNE1000015S0

002603

Pharmazeutika

Andere Sprachen

Filter